Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PK

Asan Medical Center

Status: Completed

Conditions: Gastrointestinal Stromal Tumors

Treatments: Drug: Nilotinib

Study type: Observational

Funder types: Other

Identifiers

NCT00976612

AMC0901

Details and patient eligibility

About

In patients who are receiving nilotinib, nilotinib plasma levels will be measured after 1 month of nilotinib treatment. The relationship between surgery type and nilotinib pharmakokinetic properties will be investigated in this study.

Enrollment: 17 patients

Sex: All

Ages: 15+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients with metastatic or unresectable gastrointestinal stromal tumor
• Patients receiving nilotinib after failure to imatinib and sunitinib

Trial design

17 participants in 1 patient group

Nilotinib

Description:

Patients who receive nilotinib with failure to both imatinib and sunitinib

Treatment:

Drug: Nilotinib